Press Release

IP Infusion Announces Strong Gains in Customers, Licensing and Revenue for First Half Of 2023

IP Infusion now has 600 customers, 40 ODM platforms, over 100 solution partners, and more than 1.5M switch ports sold worldwide

SANTA CLARA, Calif., Aug. 31, 2023 – IP Infusion, a leading manufacturer of carrier-grade networking software, today announced an 87% USD year-over-year revenue growth in the first half of 2023, buoyed by vigorous global sales and licensing. In the first six months of 2023, IP Infusion gained 51 new customers and added 14 new channel partners. The OcNOS Aggregation Router, Data Center, and Cell Site Router use cases lead sales, with switch and router port shipments for all OcNOS licenses sold at more than 1.5 million ports.

2023 announced customer wins include: Amplex Internet, Broadstar, DojoNetworks, MetaLINK Technologies, Multinet, Netplus, Pine Networks,  Telcom, 그리고 Vyve Broadband. These new customer wins, as well as the 163 repeat orders from existing customers in 1H23, cement IP Infusion's role as an appealing disaggregated alternative to legacy vendors including Cisco, Juniper, and Arista. Customers cite IP Infusion's attributes including its "super technology" and "flexibility at a lower price point than traditional solutions." They also noted that IP Infusion's solution strategically positions them for further expansion. IP Infusion also announced this year that the company collaborated with  NTT Corporation (NTT) for the development of Beluganos, a new network operating system to realize NTT's IOWN concept, and is providing sales and support for its global markets. 

"This continued growth over the first six months of 2023, succeeding record gains in 2022, further validates IP Infusion's position as the open network software and solution leader for service providers and data centers," said Atsushi Ogata, President and CEO of IP Infusion. "Our field-tested platform continues to build significant market share in this space through extensive use cases and successful deployments that spark innovation and lower total cost of ownership."

In addition to continued positive customer and sales momentum, IP Infusion also earned prestigious industry recognition in 1H2023.  GigaOm, leading independent global provider of technology industry insights, designated IP Infusion a Leader, Outperformer and Platform player for all of its annual 2023  Network Operating System (NOS) Radar Reports. This is the third consecutive year IP Infusion's OcNOS® platform has been identified as the most complete of the more than 20 NOS vendors GigaOm analysts evaluated, outperforming incumbent providers including Cisco and Juniper.

IP Infusion 소개

IP Infusion manufactures open network software and solutions for carriers, service providers and data centers. With hundreds of customers and thousands of deployments, IP Infusion is a market leader in Network Operating Systems. Our flagship software platform OcNOS® allows network operators to disaggregate their networks, streamline operations, and reduce Total Cost of Ownership (TCO). Network OEMs may also disaggregate network devices to expedite time to market, offer comprehensive services, and achieve carrier-grade robustness.

IP Infusion is headquartered in Santa Clara, Calif., and is a wholly owned and independently operated subsidiary of ACCESS CO., LTD. Additional information can be found at http://www.IPInfusion.com.

IP Infusion and OcNOS are trademarks or registered trademarks of IP Infusion. ACCESS is a registered trademark or trademark of ACCESS CO., LTD. in the United States, Japan and/or other countries. All other trademarks, service marks, registered trademarks, or registered service marks mentioned are the property of their respective owners.

-end-

Media Contact:

Katherine Verducci

1903 PR

kverducci@1903pr.com

408.429.5779

IP Infusion 소개

IP Infusion은 오픈 네트워킹 소프트웨어의 선도적 공급업체로, 서비스 사업자, 데이터센터, AI 패브릭 네트워크를 위한 통신사업자급 네트워크 운영체제 OcNOS를 제공합니다. 1999년부터 쌓아 온 네트워킹 전문성과 전 세계 600개 이상의 사업자를 바탕으로, IP Infusion은 Edgecore Networks, UfiSpace, Celestica 등 파트너의 검증된 개방형 하드웨어에서 개방적이고 멀티벤더이며 비용 효율적이고 유연한 네트워크 인프라를 구현합니다. IP Infusion은 ACCESS CO., LTD.(도쿄증권거래소: 4813)의 전액 출자 자회사입니다.

미디어 문의

For press inquiries, analyst briefings, or media materials, please 팀에 문의 or email pr@ipinfusion.com.

미래예측 진술

본 보도자료에는 IP Infusion의 제품, 기술 및 계획에 관한 미래예측 진술이 포함될 수 있습니다. 미래예측 진술은 공개일 현재 이용 가능한 정보에 기초하며 위험과 불확실성을 수반합니다. 실제 결과는 다를 수 있습니다. 제품 계획, 기능, 출시 시기 및 제공 여부는 예고 없이 변경될 수 있으며 약정, 약속 또는 법적 의무를 구성하지 않습니다. IP Infusion은 미래예측 진술을 갱신할 의무를 지지 않습니다.